Jump to main content.


Beryllium and compounds Quickview (CASRN 7440-41-7)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Beryllium and compounds

File First On-Line: 01/31/1987; Last Significant Revision: 04/03/1998

Category (section)
Status
Last Revised
Oral RfD Assessment On-line 04/03/1998
Inhalation RfC Assessment On-line 04/03/1998
Carcinogenicity Assessment On-line 04/03/1998
Synonyms
  • 7440-41-7
  • Beryllium
  • Beryllium-9
  • Glucinum
  • RCRA Waste Number p015
  • UN 1567
  • Beryllium and compounds
Beryllium and compounds Source Documents
Revision History
Date Section Description
04/03/1998 I.B. Inhalation RfC Assessment
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
UF RfD
Small intestinal lesions BMD10 : 4.6 x10-1 mg/kg-day 300 2 x10-3 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page


Reference Concentration for Chronic Inhalation Exposure (RfC)

Critical Effect
Point of Departure*
UF RfC
Beryllium sensitization and progression to CBD LOAEL (HEC): 2.0 x10-4 mg/m3 10 2x10-5 mg/m3

* The Point of Departure listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans)
    • Carcinogenic potential cannot be determined (Oral route)
    • Known/likely human carcinogen (Inhalation route)
  • Weight-of-Evidence Narrative:
    • B1; probable human carcinogen. Based on the limited evidence of carcinogenicity in humans exposed to airborne beryllium (lung cancer) and sufficient evidence of carcinogenicity in animals (lung cancer in rats and monkeys inhaling beryllium, lung tumors in rats exposed to beryllium via intratracheal instillation, and osteosarcomas in rabbits and possibly mice receiving intravenous or intramedullary injection), beryllium is reclassified from a B2 (inadequate human data) to a B1 probable human carcinogen (limited human data) using criteria of the 1986 Guidelines for Carcinogen Risk Assessment. Using the 1996 proposed Guidelines for Carcinogen Risk Assessment, inhaled beryllium would be characterized as a "likely" carcinogen in humans, and the human carcinogenic potential of ingested beryllium cannot be determined.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Information reviewed but value not estimated. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

Inhalation Unit Risk(s)
Extrapolation Method
2.4 x10-3 per µg/m3 Relative risk

Inhalation Concentrations at Specified Risk Levels

Risk Level
Concentration
E-4 (1 in 10,000) 4x10-2 µg/m3
E-5 (1 in 100,000) 4x10-3 µg/m3
E-6 (1 in 1,000,000) 4x10-4 µg/m3

Top of page


Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research


Local Navigation


Jump to main content.